Marco Ranucci1, Andrea Ballotta1, Umberto Di Dedda1, Ekaterina Bayshnikova1, Marco Dei Poli2, Marco Resta2, Mara Falco3, Giovanni Albano4, Lorenzo Menicanti5. 1. Department of Cardiovascular Anesthesia and Intensive Care, IRCCS Policlinico San Donato, Milan, Italy. 2. Department of General Anesthesia and Intensive Care, IRCCS Policlinico San Donato, Milan, Italy. 3. Department of Radiology, Koelliker Hospital, Turin, Italy. 4. Anesthesia and Intensive Care Department, Humanitas Gavazzeni Clinic, Bergamo, Italy. 5. Scientific Directorate, IRCCS Policlinico San Donato, Milan, Italy.
Abstract
BACKGROUND: Few observations exist with respect to the pro-coagulant profile of patients with COVID-19 acute respiratory distress syndrome (ARDS). Reports of thromboembolic complications are scarce but suggestive for a clinical relevance of the problem. OBJECTIVES: Prospective observational study aimed to characterize the coagulation profile of COVID-19 ARDS patients with standard and viscoelastic coagulation tests and to evaluate their changes after establishment of an aggressive thromboprophylaxis. METHODS: Sixteen patients with COVID-19 ARDS received a complete coagulation profile at the admission in the intensive care unit. Ten patients were followed in the subsequent 7 days, after increasing the dose of low molecular weight heparin, antithrombin levels correction, and clopidogrel in selected cases. RESULTS: At baseline, the patients showed a pro-coagulant profile characterized by an increased clot strength (CS, median 55 hPa, 95% interquartile range 35-63), platelet contribution to CS (PCS, 43 hPa; interquartile range 24-45), fibrinogen contribution to CS (FCS, 12 hPa; interquartile range 6-13.5) elevated D-dimer levels (5.5 μg/mL, interquartile range 2.5-6.5), and hyperfibrinogenemia (794 mg/dL, interquartile range 583-933). Fibrinogen levels were associated (R2 = .506, P = .003) with interleukin-6 values. After increasing the thromboprophylaxis, there was a significant (P = .001) time-related decrease of fibrinogen levels, D-dimers (P = .017), CS (P = .013), PCS (P = .035), and FCS (P = .038). CONCLUSION: The pro-coagulant pattern of these patients may justify the clinical reports of thromboembolic complications (pulmonary embolism) during the course of the disease. Further studies are needed to assess the best prophylaxis and treatment of this condition.
BACKGROUND: Few observations exist with respect to the pro-coagulant profile of patients with COVID-19acute respiratory distress syndrome (ARDS). Reports of thromboembolic complications are scarce but suggestive for a clinical relevance of the problem. OBJECTIVES: Prospective observational study aimed to characterize the coagulation profile of COVID-19ARDSpatients with standard and viscoelastic coagulation tests and to evaluate their changes after establishment of an aggressive thromboprophylaxis. METHODS: Sixteen patients with COVID-19ARDS received a complete coagulation profile at the admission in the intensive care unit. Ten patients were followed in the subsequent 7 days, after increasing the dose of low molecular weight heparin, antithrombin levels correction, and clopidogrel in selected cases. RESULTS: At baseline, the patients showed a pro-coagulant profile characterized by an increased clot strength (CS, median 55 hPa, 95% interquartile range 35-63), platelet contribution to CS (PCS, 43 hPa; interquartile range 24-45), fibrinogen contribution to CS (FCS, 12 hPa; interquartile range 6-13.5) elevated D-dimer levels (5.5 μg/mL, interquartile range 2.5-6.5), and hyperfibrinogenemia (794 mg/dL, interquartile range 583-933). Fibrinogen levels were associated (R2 = .506, P = .003) with interleukin-6 values. After increasing the thromboprophylaxis, there was a significant (P = .001) time-related decrease of fibrinogen levels, D-dimers (P = .017), CS (P = .013), PCS (P = .035), and FCS (P = .038). CONCLUSION: The pro-coagulant pattern of these patients may justify the clinical reports of thromboembolic complications (pulmonary embolism) during the course of the disease. Further studies are needed to assess the best prophylaxis and treatment of this condition.
Authors: Pietro Spagnolo; Andrea Cozzi; Riccardo Alessandro Foà; Angelo Spinazzola; Lorenzo Monfardini; Claudio Bnà; Marco Alì; Simone Schiaffino; Francesco Sardanelli Journal: Quant Imaging Med Surg Date: 2020-06
Authors: Anuja Java; Anthony J Apicelli; M Kathryn Liszewski; Ariella Coler-Reilly; John P Atkinson; Alfred Hj Kim; Hrishikesh S Kulkarni Journal: JCI Insight Date: 2020-08-06
Authors: Matthew A Sparks; Andrew M South; Andrew D Badley; Carissa M Baker-Smith; Daniel Batlle; Biykem Bozkurt; Roberto Cattaneo; Steven D Crowley; Louis J Dell'Italia; Andria L Ford; Kathy Griendling; Susan B Gurley; Scott E Kasner; Joseph A Murray; Karl A Nath; Marc A Pfeffer; Janani Rangaswami; W Robert Taylor; Vesna D Garovic Journal: Hypertension Date: 2020-09-28 Impact factor: 10.190
Authors: Margarita V Revzin; Sarah Raza; Robin Warshawsky; Catherine D'Agostino; Neil C Srivastava; Anna S Bader; Ajay Malhotra; Ritesh D Patel; Kan Chen; Christopher Kyriakakos; John S Pellerito Journal: Radiographics Date: 2020-10 Impact factor: 5.333